Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is a company with a strong pipeline of potential new therapies and a diverse portfolio of already commercialized products. They have demonstrated success in the market with their current offerings and are continuing to innovate with MNKD-201's Phase 1b data expected in 3Q26, the potential FUROSCIX ReadyFlow launch in 7/26/26, and multiple other catalysts in 2026. With a solid cash position, a potential successful launch of Afrezza in the pediatric market could provide significant upside to consensus expectations and position Afrezza as their most important growth driver.

Bears say

MannKind is facing potential erosion in Tyvaso DPI royalty, despite the market pricing in revenue growth from this product. The company's stock remains significantly undervalued, with risks including commercial execution, clinical trial and regulatory risks, as well as the possibility of a partner controlling one of the company's primary drivers for valuation. Overall, due to these factors, analysts have a negative outlook on MannKind's stock and foresee challenges in the company's performance in the near future.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jun 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.